The current financial score of Iovance Biotherapeutics Inc is 8.21, ranking 57 out of 389 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 71.43M, representing a year-over-year increase of 44.82%, while its net profit experienced a year-over-year increase of 31.95%.
Financials
7.11
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.82
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
10.00
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
8.68
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.45
Free cash flow
Relevant data have not been disclosed by the company yet.